Introduction: why ApoB is more accurate than LDL
For the past thirty years, the standard lipid panel has been built around LDL cholesterol. But LDL measures the mass of cholesterol inside atherogenic particles, not the number of the particles themselves. This is a fundamental distinction, and it explains why a patient with “normal” LDL can still have a myocardial infarction.
Apolipoprotein B-100 (ApoB) is a structural protein present in exactly one copy on each atherogenic particle: LDL, VLDL, IDL, Lp(a), and chylomicron remnants. By measuring ApoB, we obtain a direct count of all atherogenic particles in plasma.
Key point of the md_pereligyn protocol: atheroma is not formed by “cholesterol” itself, but by particle penetration through the endothelium. Each particle that passes through a damaged glycocalyx can potentially become part of a foam cell. Therefore, particle number is a more direct marker of risk than the mass of cholesterol inside those particles.
In other words: ApoB is the roll call of infantry before an assault. LDL is the total weight of their equipment. The defense is breached by numbers, not by mass.
🌀
What the discordance pattern means
When LDL and ApoB are concordant, both markers show the same risk picture. But in a substantial proportion of patients, discordance occurs: LDL appears “normal” while ApoB is high, or the reverse.
Mechanism of discordance: in metabolic dysfunction, small dense LDL (sdLDL) predominates. Each particle contains little cholesterol, but the number of particles is high. The standard lipid panel, which measures cholesterol mass, sees a “normal” result. ApoB sees the real number of atherogenic particles.
▸Large buoyant LDL (lbLDL) — more cholesterol per particle, fewer particles. LDL is high, ApoB is moderate. ▸Small dense LDL (sdLDL) — less cholesterol per particle, many particles. LDL is “normal”, ApoB is high. ▸Triglyceride-rich remnants — add ApoB beyond the LDL fraction; patients with high TG have systemically higher ApoB at the same LDL level.
The discordance pattern occurs in 30–50% of patients with metabolic syndrome, type 2 diabetes, obesity, low HDL, and high triglycerides. These are exactly the patients in whom the standard lipid panel provides false reassurance.
🌀
When ApoB and LDL diverge: 4 scenarios
Four clinical situations in which ApoB is mandatory:
•Metabolic syndrome, obesity, insulin resistance — sdLDL predominates, and ApoB is substantially higher than predicted from LDL. The risk of coronary artery disease is underestimated by the standard lipid panel. •Type 2 diabetes (T2D) — a combination of sdLDL + triglyceride-rich remnants. ApoB is often 20–30% higher than it “should be” based on LDL. This is a key scenario for missed risk in primary prevention. •Familial combined hyperlipidemia (FCHL) — many particles with normal or moderately elevated LDL. A family history of early myocardial infarction despite “normal” lipids is a reason to order ApoB. •After statin initiation — statins lower LDL more than ApoB. Residual risk is visible only through ApoB. Patients with “achieved LDL <70” may still have ApoB 90+ and ongoing progression of atherosclerosis.
In each of these scenarios, LDL-guided treatment creates a false sense of control. The real residual risk is determined only by ApoB.
🌀
ApoB target levels
ApoB levels by vascular risk category (adapted from ESC 2019, AACE 2020, NLA 2020):
▸Primary prevention, low risk (<10% over 10 years, no risk factors): ApoB <90 mg/dL ▸Intermediate risk (metabolic syndrome, prediabetes, family history): ApoB <80 mg/dL ▸High risk (type 2 diabetes, CAC > 0, familial hypercholesterolemia): ApoB <65 mg/dL ▸Secondary prevention (after myocardial infarction, stroke, revascularization): ApoB <55 mg/dL
Conversion to SI units: 1 mg/dL = 0.01 g/L. That is, <90 mg/dL = <0.9 g/L.
These thresholds are stricter than familiar “LDL targets” precisely because ApoB directly measures particle number and leaves no room for discordance-related misclassification.
🌀
Markers to test together with ApoB
ApoB does not exist in isolation. To build a complete picture of vascular risk, it is combined with:
▸ApoA1 — the structural protein of HDL. The ApoB / ApoA1 ratio is one of the best single predictors of myocardial infarction (INTERHEART study, Walldius G, J Intern Med 2004, PMID 15028089). Target <0.7 in men, <0.6 in women. ▸Lp(a) — a genetic factor, independent of lifestyle, measured once. Levels >50 mg/dL double cardiovascular risk; >180 mg/dL increases it sixfold. ▸hsCRP — a marker of vascular inflammation that complements ApoB. >2 mg/L on repeated tests indicates high risk. ▸Fasting triglycerides — an indicator of residual particles, remnants, and sdLDL. ▸TG / HDL ratio — a surrogate marker of insulin resistance and sdLDL predominance. Target <2 (mg/dL) or <0.87 (mmol/L). ▸Advanced lipid panel with sdLDL and oxLDL — atherogenic subfractions that penetrate the subendothelial space. ▸Homocysteine — a cofactor of endothelial injury. Target <8 μmol/L.
A detailed interpretation of these markers is provided in the article [Endothelium: the foundation of vascular health](/blog/endothelium-foundation-vascular-health).
🌀
Holistic protocol for lowering ApoB
Principle of the md_pereligyn protocol: lowering ApoB is not only about statins. It means working with particle production in the liver, their clearance through LDL receptors, and the oxidative environment in plasma.
### 1. Foundational diet
▸Mediterranean / DASH pattern — olive oil, fish, vegetables, nuts, legumes. ApoB reduction by 10–15% over 12 weeks. ▸Limit saturated fat to <7% of calories — palm and coconut oil, fatty beef, hard cheeses. ▸Limit trans fats — industrial baked goods, fast food, margarines. Trans fats increase ApoB more strongly than any other fat category. ▸Limit rapidly absorbed carbohydrates and fructose — hepatic fructose directly increases VLDL and triglyceride production, overloading the system with ApoB-containing particles. ▸Soluble fiber 10–25 g/day — oats, psyllium, legumes. Binds bile acids and increases LDL receptor expression.
### 2. Targeted nutraceuticals
▸Bergamot (citrus extract) 500–1000 mg/day — ApoB reduction by 15–20% over 12 weeks in double-blind studies. Activates AMPK, reduces HMG-CoA reductase activity, and increases LDL receptors. ▸Berberine 500 mg 2–3 times/day — increases LDL receptor expression via the ERK pathway. Reduces LDL and ApoB by 20–25%. Take with meals. ▸Red yeast rice (monacolin K) 3–10 mg/day — a natural HMG-CoA reductase inhibitor. An effective dose of 10 mg is pharmacologically equivalent to lovastatin 10 mg, but is often better tolerated. ▸Plant sterols 2 g/day — compete with cholesterol for intestinal absorption. Reduce LDL and ApoB by 6–10%. ▸Omega-3 (EPA+DHA) 2–4 g/day — reduce triglycerides and remnants; at high doses, may reduce ApoB. ▸Niacin (nicotinic acid) 500–1500 mg/day — reduces Lp(a) by 25% and ApoB by 15%. Use cautiously in insulin resistance.
### 3. Support insulin sensitivity
sdLDL is a consequence of insulin resistance. Without addressing the metabolic foundation, ApoB will not normalize.
▸Magnesium (glycinate / taurate) 400 mg/day — improves insulin sensitivity. ▸Chromium picolinate 200 μg/day — potentiates insulin signaling. ▸Alpha-lipoic acid 600 mg/day — antioxidant; improves insulin sensitivity. ▸Resistance training 2–3 times/week — increases muscle mass, the main “consumer” of glucose. ▸Aerobic exercise 150 min/week — reduces visceral fat, a key source of inflammatory cytokines.
### 4. Sleep and stress
▸Sleep 7–9 hours — less than 6 hours increases cortisol and stimulates hepatic VLDL production. ▸Stress management — meditation, breathing practices; chronic stress raises ApoB through cortisol. ▸Alcohol <14 g/day in men, <7 g/day in women — ethanol stimulates triglyceride and VLDL synthesis.
### 5. Pharmacotherapy
Statins and ezetimibe remain the standard of care in high and very high risk. Treatment monitoring should be based on ApoB, not LDL.
▸Rosuvastatin 5–20 mg or atorvastatin 10–40 mg — reduces ApoB by 30–45%. ▸Ezetimibe 10 mg — added when the target is not achieved; additional −15% ApoB. ▸PCSK9 inhibitors (evolocumab, alirocumab) — for familial hypercholesterolemia and high residual risk; reduce ApoB by 50%+. ▸Bempedoic acid — for patients with statin intolerance.
🌀
What does NOT work (and why)
▸Monitoring only LDL in a patient with metabolic syndrome — misses discordance; residual risk is visible only through ApoB. ▸“Normal” LDL without ApoB testing in a patient with type 2 diabetes — a false sense of control. ApoB should be measured in all patients with T2D. ▸Isolated dietary cholesterol reduction without improving insulin sensitivity — sdLDL remains, and ApoB does not normalize. ▸High doses of omega-6 oils (sunflower, corn oil) — lower LDL but increase oxidative stress and may increase the proportion of oxidized particles. ▸Low-carbohydrate ketogenic diet without ApoB monitoring — in some patients (“hyper-responders”), ApoB rises sharply on keto; testing 3 months after initiation is mandatory. ▸Annual treatment monitoring only — statins lower LDL within 4–6 weeks; ApoB should be checked 3 months after initiation or dose adjustment.
🌀
When to order ApoB
▸Any patient with CVD risk above the population baseline — once for baseline assessment ▸Suspected discordance: metabolic syndrome, type 2 diabetes, obesity, low HDL + high triglycerides ▸Family history of early myocardial infarction despite “normal” lipids ▸Monitoring statin and ezetimibe therapy — every 3–6 months ▸Decision-making about PCSK9 inhibitor therapy ▸Ketogenic or low-carbohydrate diet — check 3 months after initiation ▸Before starting hormone therapy (testosterone, estrogens) — baseline assessment
I perform a complete vascular risk assessment (ApoB, ApoA1, Lp(a), advanced lipid panel with sdLDL, hsCRP, omega-3 index) and develop a personalized ApoB-lowering protocol.
🌀
Conclusion
ApoB is displacing LDL and non-HDL as the primary metric of atherogenic risk in updated ESC (2019), AACE (2020), and NLA (2020) recommendations. This did not happen because LDL “does not work”, but because in every second patient with metabolic syndrome or diabetes, LDL and ApoB are discordant, and LDL underestimates true risk.
The principle is simple: when discordance is present, manage ApoB, not LDL. The targets are stricter — but they provide an honest picture of how many atherogenic particles attack your endothelium every day.
Treat the number of particles, not their weight.
🌀
Sources
▸Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. *JAMA Cardiol* 2019;4:1287–1295. PMID 31389988 ▸Marston NA, Giugliano RP, Melloni GEM, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes. *JAMA Cardiol* 2022;7:551–559. PMID 35583810 ▸Mortensen MB, Nordestgaard BG. Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat. *JAMA Cardiol* 2017;2:1255–1264. PMID 28419242 ▸Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. *J Intern Med* 2004;255:188–205. PMID 15028089 ▸Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J* 2020;41:111–188. PMID 31504418
Related articles: [Endothelium: the foundation of vascular health](/blog/endothelium-foundation-vascular-health), [Cholesterol without statins](/blog/kholesterin-bez-statinov).
🌀
FAQ
If my LDL is normal, do I need to test ApoB at all? Yes, especially if metabolic syndrome, type 2 diabetes, obesity, low HDL, or a family history of early myocardial infarction is present. In 30–50% of such patients, LDL is “normal” while ApoB is high. This is the discordance pattern, and it determines real risk.
Can ApoB be tested in any laboratory? Yes. ApoB is an immunoturbidimetric assay available in most large commercial laboratories. Its cost is comparable to a standard lipid panel. I recommend ordering it together with ApoA1 to calculate the ApoB / ApoA1 ratio.
How many times per year should ApoB be monitored while taking statins? The first follow-up test should be performed 6–12 weeks after initiation or dose adjustment. After achieving the target, monitor every 6 months. If the target is not achieved or tolerability is poor, monitor every 3 months with protocol adjustment.
Can ApoB be lowered without statins? Yes. In low and intermediate risk, foundational diet + bergamot / berberine / red yeast rice + improvement in insulin sensitivity can reduce ApoB by 20–30% over 3 months. In high and very high risk, statins remain first-line therapy, but the protocol enhances their effect.
Which is more important: ApoB or Lp(a)? Both are important; they measure different things. ApoB is the total number of atherogenic particles, which can be modified through diet, nutraceuticals, and statins. Lp(a) is a genetic factor, 90% determined by heredity; lifestyle has almost no effect on it, but it requires stricter ApoB targets. Lp(a) is measured once, while ApoB is measured periodically.
*This article is for informational purposes only and is not a substitute for professional medical advice. Discuss any nutraceutical, medication adjustment, or diagnostic procedure with your treating physician before starting.*
